Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Yu-Guo Yuan, Qiu-Ling Peng & Sangiliyandi Gurunathan. (2017) Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer. International Journal of Nanomedicine 12, pages 6503-6520.
Read now
Read now
Palma Fedele, Laura Orlando & Saverio Cinieri. (2017) Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opinion on Investigational Drugs 26:11, pages 1199-1206.
Read now
Read now
Susmitha Apuri & Lubomir Sokol. (2016) An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 25:6, pages 687-696.
Read now
Read now
Patrizia Mondello & Anas Younes. (2015) Emerging drugs for diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy 15:4, pages 439-451.
Read now
Read now
Suzanne F. Jones, Jeffrey R. Infante, David R. Spigel, Nancy W. Peacock, Dana S. Thompson, F. Anthony Greco, William McCulloch & Howard A. Burris III. (2012) Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors. Cancer Investigation 30:6, pages 481-486.
Read now
Read now
Ashok Kumar, Padmalatha S. Rai, Raghavendra Upadhya, Vishwanatha, K. Shama Prasada, B. S. Satish Rao & Kapettu Satyamoorthy. (2011) γ-radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines. International Journal of Radiation Biology 87:11, pages 1086-1096.
Read now
Read now
Jenny Y. Sun, Hsiuyi Tseng, Lian Xu, Zachary Hunter, Bryan Ciccarelli, Mariateresa Fulciniti, Bangmin Zhu, Kaveh Maghsoudi, Guang Yang, Ping Gong, Yangsheng Zhou, Xia Liu, Nikhil C. Munshi, Christopher J. Patterson & Steven P. Treon. (2011) Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leukemia & Lymphoma 52:9, pages 1777-1786.
Read now
Read now
Ernesto Vigna, Anna Grazia Recchia, Antonio Madeo, Massimo Gentile, Sabrina Bossio, Carla Mazzone, Eugenio Lucia, Lucio Morabito, Vincenzo Gigliotti, Laura De Stefano, Nadia Caruso, Pasquale Servillo, Stefania Franzese, Filippo Fimognari, Maria Grazia Bisconte, Carlo Gentile & Fortunato Morabito. (2011) Epigenetic regulation in myelodysplastic syndromes: implications for therapy. Expert Opinion on Investigational Drugs 20:4, pages 465-493.
Read now
Read now
Paul A Marks. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opinion on Investigational Drugs 19:9, pages 1049-1066.
Read now
Read now
Douglas Marchion & Pamela Münster. (2007) Development of histone deacetylase inhibitors for cancer treatment. Expert Review of Anticancer Therapy 7:4, pages 583-598.
Read now
Read now
Articles from other publishers (89)
Yasir S. Raouf, Abootaleb Sedighi, Mulu Geletu, Geordon A. Frere, Rebecca G. Allan, Nabanita Nawar, Elvin D. de Araujo & Patrick T. Gunning. (2023) Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy. Journal of Medicinal Chemistry.
Crossref
Crossref
Simona Camero, Matteo Cassandri, Silvia Pomella, Luisa Milazzo, Francesca Vulcano, Antonella Porrazzo, Giovanni Barillari, Cinzia Marchese, Silvia Codenotti, Miriam Tomaciello, Rossella Rota, Alessandro Fanzani, Francesca Megiorni & Francesco Marampon. (2022) Radioresistance in rhabdomyosarcomas: Much more than a question of dose. Frontiers in Oncology 12.
Crossref
Crossref
Gheath Alatrash, Chantal Saberian, Roland Bassett, Peter F. Thall, Celina Ledesma, Yoshimi Lu, May Daher, Benigno C. Valdez, Jitesh Kawedia, Uday Popat, Rohtesh Mehta, Betul Oran, Yago Nieto, Amanda Olson, Paolo Anderlini, David Marin, Chitra Hosing, Amin M. Alousi, Elizabeth J. Shpall, Gabriela Rondon, Julianne Chen, Muzaffar Qazilbash, Richard E. Champlin & Partow Kebriaei. (2022) Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and Cellular Therapy 28:8, pages 501.e1-501.e7.
Crossref
Crossref
Steven A. Manobianco, Tara Rakiewicz, Lindsay Wilde & Neil D. Palmisiano. (2022) Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. Frontiers in Oncology 12.
Crossref
Crossref
Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, Jackie Greer, B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Steven D. Gore, Nilanjan Ghosh, Amy Dezern, Amanda L. Blackford, Maria R. Baer, Lia Gore, Richard Piekarz, Jane B. Trepel & Judith E. Karp. (2021) Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leukemia Research 110, pages 106707.
Crossref
Crossref
Flávia Alves Verza, Umashankar Das, Ana Lúcia Fachin, Jonathan R. Dimmock & Mozart Marins. (2020) Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. Cancers 12:6, pages 1664.
Crossref
Crossref
Loredana Cappellacci, Diego R. Perinelli, Filippo Maggi, Mario Grifantini & Riccardo Petrelli. (2020) Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Current Medicinal Chemistry 27:15, pages 2449-2493.
Crossref
Crossref
Shital K Chattopadhyay, Subhankar Ghosh, Sarita Sarkar & Kakali Bhadra. (2019) α,ß-Didehydrosuberoylanilide hydroxamic acid (DDSAHA) as precursor and possible analogue of the anticancer drug SAHA. Beilstein Journal of Organic Chemistry 15, pages 2524-2533.
Crossref
Crossref
Marina Barcena-Varela, Leticia Colyn & Maite G. Fernandez-Barrena. (2019) Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis. International Journal of Molecular Sciences 20:10, pages 2507.
Crossref
Crossref
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami & Dimitrios Dimitroulis. 2019. Pharmacoepigenetics. Pharmacoepigenetics
501
521
.
Prakruti Trivedi, Nilanjan Adhikari, Sk. Abdul Amin, Tarun Jha & Balaram Ghosh. (2018) Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects. European Journal of Pharmaceutical Sciences 124, pages 165-181.
Crossref
Crossref
Aline A Zuma & Wanderley de Souza. (2018) Histone deacetylases as targets for antitrypanosomal drugs. Future Science OA 4:8, pages FSO325.
Crossref
Crossref
Jyoti Swaroop Kumar, Shubhankar Suman & Sudhir Chandna. (2017) Radioresistant Sf9 insect cells readily undergo an intrinsic mode of apoptosis in response to histone deacetylase (HDAC) inhibition. Molecular and Cellular Biochemistry 444:1-2, pages 207-218.
Crossref
Crossref
Evanthia Galanis, S Keith Anderson, C Ryan Miller, Jann N Sarkaria, Kurt Jaeckle, Jan C Buckner, Keith L Ligon, Karla V Ballman, Dennis F MooreJrJr, Michael Nebozhyn, Andrey Loboda, David Schiff, Manmeet Singh Ahluwalia, Eudocia Q Lee, Elizabeth R Gerstner, Glenn J Lesser, Michael Prados, Stuart A Grossman, Jane Cerhan, Caterina Giannini & Patrick Y Wen. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-Oncology 20:4, pages 546-556.
Crossref
Crossref
Catherine G. Chung, Brian Poligone & Peter W. Heald. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
331
342
.
Chiara Zagni, Venerando Pistarà, Luciana A. Oliveira, Rogerio M. Castilho, Giovanni Romeo, Ugo Chiacchio & Antonio Rescifina. (2017) Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design. European Journal of Medicinal Chemistry 141, pages 188-196.
Crossref
Crossref
Jin Li, Changgeng Qian, Qianqian Zhou, Jiwei Li, Kunlun Li & Pingyong Yi. (2017) RETRACTED: BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma. Biochemical and Biophysical Research Communications 491:4, pages 939-945.
Crossref
Crossref
Said M. Elshafae, Nicole A. Kohart, Lucas A. Altstadt, Wessel P. Dirksen & Thomas. J. Rosol. (2017) The Effect of a Histone Deacetylase Inhibitor (AR‐42) on Canine Prostate Cancer Growth and Metastasis. The Prostate 77:7, pages 776-793.
Crossref
Crossref
Shou-Chieh Wang, Shou-Tsung Wang, Hung-Te Liu, Xiang-Yu Wang, She-Ching Wu, Lei-Chin Chen & Yi-Wen Liu. (2017) Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1-survivin downregulation at the late phase of treatment. Oncology Reports 38:3, pages 1587-1596.
Crossref
Crossref
Sasha Stephen, Ellen J. Kim, Camille E. Introcaso, Stephen K. Richardson & Alain H. Rook. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
715
740
.
Jie Ji, Benigno C. Valdez, Yang Li, Yan Liu, Esmeralda C. Teo, Yago Nieto, Richard E. Champlin & Borje S. Andersson. (2016) Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Experimental Hematology 44:6, pages 458-465.
Crossref
Crossref
Tor Paaske Utheim, Panagiotis Salvanos, Øygunn Aass Utheim, Sten Ræder, Lara Pasovic, Ole Olstad, Maria Fideliz de la Paz & Amer Sehic. (2016) Transcriptome Analysis of Cultured Limbal Epithelial Cells on an Intact Amniotic Membrane following Hypothermic Storage in Optisol-GS. Journal of Functional Biomaterials 7:1, pages 4.
Crossref
Crossref
B C Valdez, J E Brammer, Y Li, D Murray, Y Liu, C Hosing, Y Nieto, R E Champlin & B S Andersson. (2015) Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer Journal 5:10, pages e357-e357.
Crossref
Crossref
Liudmila Zakharova, Hikmet Nural-Guvener, Lorraine Feehery, Snjezana Popovic-Sljukic & Mohamed A. Gaballa. (2015) Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model. Stem Cells Translational Medicine 4:9, pages 1086-1096.
Crossref
Crossref
Ahmed Sawas, Dejan Radeski & Owen A. O’Connor. (2015) Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Therapeutic Advances in Hematology 6:4, pages 202-208.
Crossref
Crossref
Roy Lardenoije, Artemis Iatrou, Gunter Kenis, Konstantinos Kompotis, Harry W.M. Steinbusch, Diego Mastroeni, Paul Coleman, Cynthia A. Lemere, Patrick R. Hof, Daniel L.A. van den Hove & Bart P.F. Rutten. (2015) The epigenetics of aging and neurodegeneration. Progress in Neurobiology 131, pages 21-64.
Crossref
Crossref
Ferdinando ChiaradonnaIros BarozziClaudia MiccoloGabriele BucciRoberta PaloriniLorenzo FornasariOronza A. BotrugnoGiancarlo PruneriMichele MasulloAlfonso PassafaroViviana E. GalimbertiValeria R. FantinVictoria M. RichonSalvatore PeceGiuseppe VialePier Paolo Di FioreGiulio DraettaPier Giuseppe PelicciSaverio MinucciSusanna Chiocca. (2015) Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxidants & Redox Signaling 23:1, pages 15-29.
Crossref
Crossref
Pusoon Chun. (2015) Histone deacetylase inhibitors in hematological malignancies and solid tumors. Archives of Pharmacal Research 38:6, pages 933-949.
Crossref
Crossref
Yu-Gang Wang. (2015) Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World Journal of Gastroenterology 21:27, pages 8326.
Crossref
Crossref
Eun Jung Choi, Bong Jun Cho, David J Lee, Yeo Hyeon Hwang, Sun Ha Chun, Hans H Kim & In Ah Kim. (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14:1.
Crossref
Crossref
Prithviraj Bose, Yun Dai & Steven Grant. (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. Pharmacology & Therapeutics 143:3, pages 323-336.
Crossref
Crossref
Mati Ur Rehman, Paras Jawaid, Yoko Yoshihisa, Peng Li, Qing Li Zhao, Koichi Narita, Tadashi Katoh, Takashi Kondo & Tadamichi Shimizu. (2014) Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells. Chemico-Biological Interactions 221, pages 24-34.
Crossref
Crossref
Antonio Rossi. (2014) Potential role of histone deacetylase inhibitors in the treatment of advanced non-small-cell lung cancer. Lung Cancer Management 3:3, pages 255-261.
Crossref
Crossref
Michael Batalo, Prithviraj Bose, Beata Holkova & Steven Grant. 2014. Resistance to Proteasome Inhibitors in Cancer. Resistance to Proteasome Inhibitors in Cancer
149
179
.
Claire Westerland & Tom C. Karagiannis. 2014. Molecular mechanisms and physiology of disease. Molecular mechanisms and physiology of disease
81
112
.
Paul A. Marks. 2015. Molecular Oncology. Molecular Oncology
912
920
.
Mohamed E. Shaker, Ayaz Ghani, Gamal E. Shiha, Tarek M. Ibrahim & Wajahat Z. Mehal. (2013) Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833:8, pages 1992-2003.
Crossref
Crossref
Christina E. Wells, Srividya Bhaskara, Kristy R. Stengel, Yue Zhao, Bianca Sirbu, Benjamin Chagot, David Cortez, Dineo Khabele, Walter J. Chazin, Andrew Cooper, Vincent Jacques, James Rusche, Christine M. Eischen, Laura Y. McGirt & Scott W. Hiebert. (2013) Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma. PLoS ONE 8:7, pages e68915.
Crossref
Crossref
L-N Zhang, J-Y Li & W Xu. (2012) A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Therapy 20:1, pages 1-7.
Crossref
Crossref
Jack-Michel Renoir. (2012) Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. Steroids 77:12, pages 1249-1261.
Crossref
Crossref
A. Druz, M. Betenbaugh & J. Shiloach. (2012) Glucose depletion activates mmu-miR-466h-5p expression through oxidative stress and inhibition of histone deacetylation. Nucleic Acids Research 40:15, pages 7291-7302.
Crossref
Crossref
Paul V. LicciardiFaith A.A. KwaKatherine VerverisNatasha Di CostanzoAneta BalcerczykMimi L. TangAssam El-OstaTom C. Karagiannis. (2012) Influence of Natural and Synthetic Histone Deacetylase Inhibitors on Chromatin. Antioxidants & Redox Signaling 17:2, pages 340-354.
Crossref
Crossref
Abhinav Sidana, Muwen Wang, Shabana Shabbeer, Wasim H. Chowdhury, George Netto, Shawn E. Lupold, Michael Carducci & Ronald Rodriguez. (2012) Mechanism of Growth Inhibition of Prostate Cancer Xenografts by Valproic Acid. Journal of Biomedicine and Biotechnology 2012, pages 1-9.
Crossref
Crossref
Abraham Jacob, Janet Oblinger, Matthew L. Bush, Victoria Brendel, Griffin Santarelli, Abhik R. Chaudhury, Samuel Kulp, Krista M. D. La Perle, Ching-Shih Chen, Long-Sheng Chang & D. Bradley Welling. (2012) Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope 122:1, pages 174-189.
Crossref
Crossref
Ruman Rahman & Richard Grundy. (2011) Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy. International Journal of Cancer 129:12, pages 2765-2774.
Crossref
Crossref
Juan Carlos Ramos & Izidore S. Lossos. (2011) Newly Emerging Therapies Targeting Viral-Related Lymphomas. Current Oncology Reports 13:5, pages 416-426.
Crossref
Crossref
Hirak S. Basu, Amy Mahlum, Farideh Mehraein-Ghomi, Stacy J. Kegel, Song Guo, Noel R. Peters & George Wilding. (2010) Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemotherapy and Pharmacology 67:3, pages 705-715.
Crossref
Crossref
Paul A. Marks. (2010) Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1799:10-12, pages 717-725.
Crossref
Crossref
Amanda Copeland, Daniela Buglio & Anas Younes. (2010) Histone deacetylase inhibitors in lymphoma. Current Opinion in Oncology 22:5, pages 431-436.
Crossref
Crossref
J.-H. Lee, M. L. Choy, L. Ngo, S. S. Foster & Paul A. Marks. (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences 107:33, pages 14639-14644.
Crossref
Crossref
Leigh Ellis & Roberto Pili. (2010) Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals 3:8, pages 2441-2469.
Crossref
Crossref
Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Maria K. Angelopoulou & Evangelos Terpos. (2010) Incorporating novel agents in the treatment of myelodysplastic syndromes. Leukemia Research 34:1, pages 6-17.
Crossref
Crossref
Tamer E. FandyJames G. HermanPatrick KernsAnchalee JiemjitElizabeth A. SugarSi-Ho ChoiAllen S. YangTimothy AucottTianna DausesRosalie Odchimar-ReissigJonathan LichtMelanie J. McConnellChris NasrallahMarianne K. H. KimWeijia ZhangYezou Sun, Anthony Murgo, Igor Espinoza-Delgado, Katharine OteizaIbitayo OwoeyeLewis R. SilvermanSteven D. GoreHetty E. Carraway. (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:13, pages 2764-2773.
Crossref
Crossref
Bruno Cadot, Mirko Brunetti, Sabina Coppari, Silvia Fedeli, Emanuele de Rinaldis, Claudio Dello Russo, Paola Gallinari, Raffaele De Francesco, Christian Steinkühler & Gessica Filocamo. (2009) Loss of Histone Deacetylase 4 Causes Segregation Defects during Mitosis of p53-Deficient Human Tumor Cells. Cancer Research 69:15, pages 6074-6082.
Crossref
Crossref
Sriram Balasubramanian, Erik Verner & Joseph J. Buggy. (2009) Isoform-specific histone deacetylase inhibitors: The next step?. Cancer Letters 280:2, pages 211-221.
Crossref
Crossref
In Ah Kim, Mina No, Jang Mi Lee, Jin Hee Shin, Jee Sun Oh, Eun Jung Choi, Il Han Kim, Peter Atadja & Eric J. Bernhard. (2009) Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6. Radiotherapy and Oncology 92:1, pages 125-132.
Crossref
Crossref
Savita Bhalla, Sriram Balasubramanian, Kevin David, Mint Sirisawad, Joseph Buggy, Lauren Mauro, Sheila Prachand, Richard Miller, Leo I. Gordon & Andrew M. Evens. (2009) PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. Clinical Cancer Research 15:10, pages 3354-3365.
Crossref
Crossref
Lucia Altucci & Saverio Minucci. (2009) Epigenetic therapies in haematological malignancies: Searching for true targets. European Journal of Cancer 45:7, pages 1137-1145.
Crossref
Crossref
Yang Yang, Ying Zhao, Wenjuan Liao, Jing Yang, Lipeng Wu, Zhixing Zheng, Yu Yu, Wen Zhou, Lian Li, Jingnan Feng, Haiying Wang & Wei-Guo Zhu. (2009) Acetylation of FoxO1 Activates Bim Expression to Induce Apoptosis in Response to Histone Deacetylase Inhibitor Depsipeptide Treatment. Neoplasia 11:4, pages 313-IN1.
Crossref
Crossref
Margaret T. Kasner & Selina M. Luger. (2009) Update on the therapy for myelodysplastic syndrome. American Journal of Hematology 84:3, pages 177-186.
Crossref
Crossref
Vanessa Duong, Caroline Bret, Lucia Altucci, Antonello Mai, Céline Duraffourd, Julie Loubersac, Pierre-Olivier Harmand, Sandrine Bonnet, Sergio Valente, Thierry Maudelonde, Vincent Cavailles & Nathalie Boulle. (2008) Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells. Molecular Cancer Research 6:12, pages 1908-1919.
Crossref
Crossref
Steven D. Gore & Evelyn R. Hermes-DeSantis. (2008) Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches. Cancer Control 15:4_suppl, pages 40-49.
Crossref
Crossref
Roberto R. Rosato, Jorge A. Almenara, Sonia C. Maggio, Stefanie Coe, Peter Atadja, Paul Dent & Steven Grant. (2008) Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics 7:10, pages 3285-3297.
Crossref
Crossref
Cesare Gridelli, Antonio Rossi & Paolo Maione. (2008) The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Critical Reviews in Oncology/Hematology 68:1, pages 29-36.
Crossref
Crossref
Olaia Martínez-Iglesias, Lidia Ruiz-Llorente, Ruth Sánchez-Martínez, Laura García, Alberto Zambrano & Ana Aranda. (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clinical and Translational Oncology 10:7, pages 395-398.
Crossref
Crossref
Ivan Kalousek, Barbora Brodska, Petra Otevrelova & Pavla Röselova. (2008)
BimEL‐dependent apoptosis induced in peripheral blood lymphocytes with
n
‐butyric acid is moderated by variation in expression of c‐myc and p21(WAF1)
. Cell Biochemistry and Function 26:4, pages 509-521.
Crossref
Crossref
Pablo Ramirez & John F. DiPersio. (2008) Therapy Options in Imatinib Failures. The Oncologist 13:4, pages 424-434.
Crossref
Crossref
S Inoue, R Walewska, M J S Dyer & G M Cohen. (2008) Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 22:4, pages 819-825.
Crossref
Crossref
Elizabeth A. Griffiths & Steven D. Gore. (2008) DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes. Seminars in Hematology 45:1, pages 23-30.
Crossref
Crossref
Francis Lee, Abderrahim Fandi & Maurizio Voi. (2008) Overcoming kinase resistance in chronic myeloid leukemia. The International Journal of Biochemistry & Cell Biology 40:3, pages 334-343.
Crossref
Crossref
Ellen J. Kim, Camille E. Introcaso, Stephen K. Richardson & Alain H. Rook. 2008. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
411
437
.
Milos Dokmanovic, Cathy Clarke & Paul A. Marks. (2007) Histone Deacetylase Inhibitors: Overview and Perspectives. Molecular Cancer Research 5:10, pages 981-989.
Crossref
Crossref
Milos Dokmanovic, Gisela Perez, Weisheng Xu, Lang Ngo, Cathy Clarke, Raphael B. Parmigiani & Paul A. Marks. (2007) Histone deacetylase inhibitors selectively suppress expression of HDAC7. Molecular Cancer Therapeutics 6:9, pages 2525-2534.
Crossref
Crossref
J Golay, L Cuppini, F Leoni, C Micò, V Barbui, M Domenghini, L Lombardi, A Neri, A M Barbui, A Salvi, P Pozzi, G Porro, P Pagani, G Fossati, P Mascagni, M Introna & A Rambaldi. (2007) The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 21:9, pages 1892-1900.
Crossref
Crossref
Keith B. Glaser. (2007) HDAC inhibitors: Clinical update and mechanism-based potential. Biochemical Pharmacology 74:5, pages 659-671.
Crossref
Crossref
W S Xu, R B Parmigiani & P A Marks. (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:37, pages 5541-5552.
Crossref
Crossref
S Inoue, J Riley, T W Gant, M J S Dyer & G M Cohen. (2007) Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21:8, pages 1773-1782.
Crossref
Crossref
Hetty E. Carraway & Steven D. Gore. (2007) Addition of Histone Deacetylase Inhibitors in Combination Therapy. Journal of Clinical Oncology 25:15, pages 1955-1956.
Crossref
Crossref
Paola Gallinari, Stefania Di Marco, Phillip Jones, Michele Pallaoro & Christian Steinkühler. (2007) HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Research 17:3, pages 195-211.
Crossref
Crossref
Roberto R. Rosato, Jorge A. Almenara, Sarah S. Kolla, Sonia C. Maggio, Stefanie Coe, Maria S. Giménez, Paul Dent & Steven Grant. (2007) Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Molecular Cancer Therapeutics 6:2, pages 692-702.
Crossref
Crossref
Yukihiko Kato, Brenda C. Salumbides, Xiao-Fei Wang, David Z. Qian, Simon Williams, Yongfeng Wei, Tolib B. Sanni, Peter Atadja & Roberto Pili. (2007)
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-
cis
-retinoic acid in human malignant melanoma
. Molecular Cancer Therapeutics 6:1, pages 70-81.
Crossref
Crossref
Tamer E. Fandy, Hetty Carraway & Steven D. Gore. (2007) DNA Demethylating Agents and Histone Deacetylase Inhibitors in Hematologic Malignancies. The Cancer Journal 13:1, pages 40-48.
Crossref
Crossref
Tamer Fandy, Hetty Carraway & Steven D. Gore. 2007. Acute Myelogenous Leukemia. Acute Myelogenous Leukemia
275
291
.
Ellen J. Kim, Julie Lin, Jacqueline M. Junkins- Hopkins, Carmela C. Vittorio & Alain H. Rook. (2006) Mycosis fungoides and sezary syndrome: An update. Current Oncology Reports 8:5, pages 376-386.
Crossref
Crossref
Satoshi Inoue, Antonello Mai, Martin J.S. Dyer & Gerald M. Cohen. (2006) Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis. Cancer Research 66:13, pages 6785-6792.
Crossref
Crossref
Cristiana Foglietti, Gessica Filocamo, Enrico Cundari, Emanuele De Rinaldis, Armin Lahm, Riccardo Cortese & Christian Steinkühler. (2006) Dissecting the Biological Functions of Drosophila Histone Deacetylases by RNA Interference and Transcriptional Profiling. Journal of Biological Chemistry 281:26, pages 17968-17976.
Crossref
Crossref
In Ah Kim, Jin Hee Shin, Il Han Kim, Jin Ho Kim, Jae Sung Kim, Hong Gyun Wu, Eui Kyu Chie, Sung Whan Ha, Charn Il Park & Gary D. Kao. (2006) Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53. Clinical Cancer Research 12:3, pages 940-949.
Crossref
Crossref
Gary K. Scott, Michael D. Mattie, Crystal E. Berger, Stephen C. Benz & Christopher C. Benz. (2006) Rapid Alteration of MicroRNA Levels by Histone Deacetylase Inhibition. Cancer Research 66:3, pages 1277-1281.
Crossref
Crossref
Patrick C. Tapia. (2006) Histone-deacetylase inhibitors may accelerate the aging process in stem cell-dependent mammals: Stem cells, Ku70, and Drosophila at the crossroads. Medical Hypotheses 66:2, pages 332-336.
Crossref
Crossref